What is the recommended diagnostic workup and management for Fanconi anemia?

Fanconi Anemia: Diagnostic Workup and Management

Diagnostic Confirmation

Diagnosis of Fanconi anemia must be confirmed by chromosomal breakage studies measuring DNA breaks after exposure to diepoxybutane (DEB) or mitomycin C (MMC), combined with germline genetic sequencing. 1

Primary Diagnostic Testing

• Chromosomal breakage analysis (CBA) on peripheral blood lymphocytes detects approximately 91.5% of FA cases and serves as the initial screening test 2
• FANCD2 monoubiquitination assay by immunoblot is more sensitive, detecting 97% of FA cases, and provides rapid diagnosis within days rather than weeks required for traditional cytogenetic analysis 2, 3
• The absence of monoubiquitinated FANCD2 isoform correlates directly with FA diagnosis and distinguishes FA from other bone marrow failure syndromes and chromosomal instability disorders 3

Critical Diagnostic Pitfall: Somatic Mosaicism

When blood-based testing is inconclusive or clinical suspicion remains high despite negative results, fibroblast analysis is mandatory to detect hematopoietic somatic mosaicism, which can cause false-negative results in blood samples 4. In a cohort of 87 bone marrow failure patients, fibroblast testing identified 3 additional FA patients (43% of total FA cases) who were missed by blood testing alone 4.

• Flow cytometry-based MMC sensitivity testing in skin fibroblasts provides a reliable alternative method for evaluating FA phenotype 4
• Approximately 6 of 124 FA patients (4.8%) exhibit mosaicism that can obscure diagnosis 5

Genetic Analysis

• Exome sequencing identifies FA genotypes in 95.7% of patients and should include enhanced bioinformatics to detect single nucleotide variants and copy number variations 2
• FANCA mutations are most frequent (60-70%), followed by FANCC (10-14%) and FANCG (8-10%) 1, 2
• Variants of unknown significance require functional validation by lentiviral complementation assay 2
• FANCD1/BRCA2 and FANCN/PALB2 mutations confer exceptionally high risk for early brain tumors (medulloblastoma) before age 6 and Wilms tumor, requiring modified surveillance 1

High-Risk Screening Indications

Genetic screening should be performed in pediatric patients with: 6

• Unexplained short stature without identifiable endocrine or nutritional causes (6.7% positive rate)
• Congenital anomalies including skeletal malformations, craniofacial deformities, abnormal skin pigmentation, renal anomalies, cardiac malformations, or gonadal anomalies (13.3% positive rate)
• Family history suggestive of FA or early-onset blood cancers (28.6% positive rate)

Clinical Phenotype Recognition

Approximately 60-75% of FA patients exhibit physical abnormalities, though 25-40% have no obvious congenital features, making diagnosis challenging 1. Common findings include:

• Skeletal malformations of upper limbs and short stature (most common) 5
• Abnormal skin pigmentation 1
• Ophthalmic, renal, cardiac, and gonadal anomalies 1
• Endocrine disorders: growth hormone deficiency, hypothyroidism, diabetes 1

The absence of bone marrow failure does not exclude FA diagnosis, and malignancy can precede BMF diagnosis. 1

Management and Surveillance

Hematologic Monitoring

• More than 95% of FA patients develop bone marrow failure, with 70% risk of severe BMF by age 50 1
• Regular complete blood counts with differential are essential, as the majority are diagnosed with BMF in childhood 1
• 11% of FA patients develop cancer at pediatric age, with cumulative incidence of MDS (50%), leukemia (10%), and solid tumors (20-30%) by age 50 1

Malignancy Surveillance

Head and neck squamous cell carcinoma (HNSCC) surveillance is critical, as this represents the most common solid tumor in FA patients, developing much earlier than in the general population 1. The risk of solid tumors increases substantially after hematopoietic stem cell transplantation 1, 7.

Endocrine Complications in Adults

Adults with FA require monitoring for: 7

• Hypothyroidism (42% prevalence)
• Diabetes (10% prevalence)
• Low bone mineral density (51% prevalence)
• Low body mass index (31% prevalence)

Radiation Exposure Precautions

Minimize all radiation exposure, as no amount of radiation should be considered absolutely safe in FA patients due to their DNA repair defects 1. This includes judicious use of diagnostic imaging and consideration of radiation-free alternatives when possible.

Transplantation Considerations

Patients with undiagnosed FA who receive standard-dose conditioning regimens for HSCT experience major toxicity due to cellular hypersensitivity to DNA-damaging agents 4. This underscores the critical importance of accurate pre-transplant diagnosis, particularly in bone marrow failure patients without obvious FA phenotype.

• FA patients require reduced-intensity conditioning regimens 4
• Post-transplant patients face higher solid tumor risk and require intensified surveillance 1, 7

Emerging Therapeutic Approaches

For FA-associated HNSCC, which has limited treatment options due to germline DNA repair defects precluding most chemotherapies: 8

• FDA-approved EGFR-targeted therapies show efficacy in tumors with high EGFR/p-EGFR expression
• Bcl-2 inhibitor venetoclax demonstrates activity in FA-HNSCC overexpressing Bcl-2
• These precision medicine approaches offer alternatives when surgery and radiation are insufficient